Related references
Note: Only part of the references are listed.
Review
Oncology
Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review
Michele Fiore et al.
Summary: Background and objective: Despite advances in the multidisciplinary management of pancreatic cancer, the prognosis remains poor due to early disease progression. This review provides an update on the current status of pre-treatment evaluation for pancreatic cancer. Methods: An extensive review of relevant articles on traditional imaging, functional imaging, and minimally invasive surgical procedures was conducted. Prospective observational studies, retrospective analyses, and meta-analyses were included. Key content and findings: Each imaging modality has its own advantages and limitations, with reported sensitivity, specificity, and accuracy. The increasing role of neoadjuvant therapy and patient-tailored treatment selection based on tumor staging are discussed. Conclusions: A multimodal pre-treatment workup improves staging accuracy and guides treatment selection for pancreatic cancer patients.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2023)
Article
Oncology
The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial
Jelle C. van Dongen et al.
Summary: This study aimed to evaluate the value of staging laparoscopy in detecting occult metastases in patients with resectable or borderline resectable pancreatic cancer. The results showed that staging laparoscopy could detect occult metastases in about 10% of patients, and these patients were more likely to receive palliative systemic chemotherapy.
EJSO (2023)
Article
Oncology
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne et al.
Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.
JOURNAL OF CLINICAL ONCOLOGY (2022)